What question did this study set out to answer?

This study aims to investigate factors contributing to racial disparities in pathologic complete response in HER2-positive breast cancer patients after neoadjuvant chemotherapy.

February 19, 2026Clinical Cancer Research

Abstract PS4-12-12: Racial Disparities in Pathologic Complete Response in Patients with HER2 Positive Breast Cancer Treated with Neoadjuvant Chemotherapy

View Full Paper

Ask AI

Bookmark

Authors

RMRegina Matar-UjvaryCleveland Clinic RRRahul RanganCleveland Clinic WWW. WeiCleveland Clinic

Discussion

Member takes

Implication

This retrospective study identifies factors affecting pathologic complete response in HER2-positive breast cancer, highlighting racial disparities.

Key Points

This study aims to investigate factors contributing to racial disparities in pathologic complete response in HER2-positive breast cancer patients after neoadjuvant chemotherapy.
Conducted a retrospective review of an institutional tumor registry from 2016 to 2022.
Identified women with HER2-positive breast cancers treated with neoadjuvant chemotherapy and surgery.
Compared sociodemographic, clinicopathologic features, and treatment variables among racial groups.
Black patients achieved pathologic complete response (41%) less often than White (54%) and Other (63%) groups, though not statistically significant (p=0.11).
Factors like age <50 years, private insurance, hormone receptor-negative subtype, HER2 score of 3+, and grade 3 disease were associated with higher pCR likelihood.
Race and other clinical factors were not linked to achieving pCR.

Cite This Study

Matar-Ujvary et al. (2026) studied this question.

synapsesocial.com/papers/6996a8b5ecb39a600b3efbf0 https://doi.org/10.1158/1557-3265.sabcs25-ps4-12-12

View Full Paper

Ask AI

Bookmark

Implication

This retrospective study identifies factors affecting pathologic complete response in HER2-positive breast cancer, highlighting racial disparities.

Abstract PS4-12-12: Racial Disparities in Pathologic Complete Response in Patients with HER2 Positive Breast Cancer Treated with Neoadjuvant Chemotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract PS4-12-12: Racial Disparities in Pathologic Complete Response in Patients with HER2 Positive Breast Cancer Treated with Neoadjuvant Chemotherapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider